ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 2719

Can Annexin A1 Expression on Neutrophils Distinguish Adult IgA Vasculitis from Other Small Vessel Vasculitides?

Tadeja Kuret1, Katja Lakota1,2, Polona Žigon1, Manca Ogrič1, Boris Lestan1, Snezna Sodin Semrl1,2, Saša Čučnik1,3, Matija Tomšič1,4 and Alojzija Hočevar1, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Faculty of Mathematics, Natural Science and Information Technology, University of Primorska, Koper, Slovenia, 3Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia, 4University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: Annexins, Immunoglobulin (IG), neutrophils and vasculitis

Session Information

Date: Tuesday, November 7, 2017

Title: Vasculitis Poster III: Other Vasculitis Syndromes

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Immunoglobulin A vasculitis (IgAV, formerly Henoch–Schönlein purpura) is a small vessel, immune complex vasculitis characterized by dominant IgA deposits in the vascular wall. Clinical symptoms include skin, joint, gastrointestinal (GI) or renal involvement. Adults frequently develop more severe disease than children1. Recently, the neutrophil to lymphocyte ratio (NLR) has been proposed as a potential marker for predicting systemic involvement in adult IgAV2. Moreover, neutrophil phenotypes have been shown to be differentially involved in disease progression of other vasculitides3. We aimed to determine the percentage of neutrophils, T- and B-cells, NLR and mean fluorescence intensity (MFI) of CD62L and Annexin A1 (AnxA1) on CD16+ neutrophils in peripheral blood of newly diagnosed, biopsy-proven adult patients with IgAV compared to other small vessel vasculitides (non-IgAV) and healthy blood donors (HBD).

Methods: Flow cytometry of stained, lysed and fixed whole blood was performed in IgAV (n=15; n=9 for AnxA1), non-IgAV patients (n=11; n=6 for AnxA1) and HBD (n=16; n=7 for AnxA1). The diagnoses of non-IgAV included infection-associated small vessel vasculitis, vasculitis associated with tubulointerstitial nephritis and uveitis, ANCA vasculitis and, cryoglobulinemic vasculitis. IgAV patients were further divided into two groups based on organ involvement (patients with isolated skin involvement; n=9 and patients with concomitant renal or GI involvement; n=6). In the IgAV group only one patient had concomitant infection (of urinary tract).

Results: Percentage of CD16+ neutrophils and NLR were significantly higher, while percentages of T- (CD3+) and B-cells (CD19+) were significantly lower in newly diagnosed IgAV and non-IgAV cases compared to HBD. Expression of AnxA1 was significantly elevated on CD16+ neutrophils in IgAV (16.1 (12.9-19.4); median (IQR)) compared to non-IgAV (10.0 (8.1-15.2); p=0.029 (Table 1)). IgAV patients with skin and renal or GI involvement had a significantly higher percentage of CD16+ neutrophils (77.1 (67.2-83.6)) compared to skin limited IgAV cases (64.5 (57.1-69.1); p=0.012).

Table 1: Neutrophil/Lymphocyte percentages, their ratio and expression of AnxA1 and CD62L in IgAV patients as compared to HBD and non-IgAV patients

MEDIAN (IQR)

P VALUE

HBD

IgAV

Non-IgAV

HBD vs. IgAV

HBD

vs.

non-IgAV

IgAV

vs.

non-IgAV

Neutrophils (%)

51.0 (47.1-56.9)

67.5 (63.6-73.3)

69.0 (59.4-78.2)

<0.0001

<0.0001

0.9586

T-cells (%)

26.4 (23.0-31.8)

16.6 (10.2-21.4)

17.8 (19.2-21.4)

0.0004

0.0096

0.8355

B-cells (%)

3.8 (2.9-4.7)

2.4 (1.6-2.9)

1.5 (0.9-2.7)

0.0042

0.0083

0.3502

NLR

1.7 (1.4-2.1)

3.3 (2.8-5.8)

3.4 (2.2-7.1)

0.0001

0.0043

0.8967

Annexin A1 (MFI)

21.3 (18.4-23.7)

16.1 (12.9-19.4)

10.0 (8.1-15.2)

0.0549

0.0023

0.0290

CD62L (MFI)

56.4 (44.9-72.0)

83.7 (58.6-102.8)

92.2 (61.0-127.1)

0.0575

0.0256

0.4743

Conclusion: Our study reports that neutrophil AnxA1 might represent a good surface marker for distinguishing IgAV from other small vessel vasculitides.

References:

  1. Jennette JC, Falk RJ, Bacon PA. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1-11.
  2. Nagy GE, Kemény L, Bata-Csörgő Z. Neutrophil-to-lymphocyte ratio: A biomarker for predicting systemic involvement in adult IgA vasculitis patients [published online Feb 21 2017]. J Eur Acad Dermatol Venereol. 2017. doi: 10.1111/jdv.14176. 2017.
  3. Nadkarni S et al. Investigational analysis reveals a potential role for neutrophils in GCA disease progression. Circ. Res. 2014;114:242-48.

Disclosure: T. Kuret, None; K. Lakota, None; P. Žigon, None; M. Ogrič, None; B. Lestan, None; S. Sodin Semrl, None; S. Čučnik, None; M. Tomšič, None; A. Hočevar, None.

To cite this abstract in AMA style:

Kuret T, Lakota K, Žigon P, Ogrič M, Lestan B, Sodin Semrl S, Čučnik S, Tomšič M, Hočevar A. Can Annexin A1 Expression on Neutrophils Distinguish Adult IgA Vasculitis from Other Small Vessel Vasculitides? [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/can-annexin-a1-expression-on-neutrophils-distinguish-adult-iga-vasculitis-from-other-small-vessel-vasculitides/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-annexin-a1-expression-on-neutrophils-distinguish-adult-iga-vasculitis-from-other-small-vessel-vasculitides/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology